Work

Efficacy and safety of once-weekly semaglutide vs exenatide ER after 56 Weeks in subjects with type 2 diabetes (SUSTAIN 3)

Year: 2016

Type: article

Source: Diabetes Research and Clinical Practice

DOI: 10.1016/s0168-8227(16)31023-3

Authors: Andrew Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders Gaarsdal Holst, Miriam Annett, Vanita Aroda

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2551448889

FWCI: 4.677

Cites:

Cited by: 14

Related to: 10